BidaskClub lowered shares of Epizyme (NASDAQ:EPZM) from a sell rating to a strong sell rating in a research note issued to investors on Wednesday morning.
Other research analysts also recently issued research reports about the stock. Cowen reissued a buy rating on shares of Epizyme in a research report on Monday, September 24th. Cann restated a buy rating and issued a $27.00 price target on shares of Epizyme in a report on Thursday, August 2nd. ValuEngine upgraded shares of Epizyme from a sell rating to a hold rating in a report on Thursday, July 26th. Morgan Stanley set a $12.00 price target on shares of Epizyme and gave the company a hold rating in a report on Friday, September 7th. Finally, Zacks Investment Research upgraded shares of Epizyme from a hold rating to a buy rating and set a $15.00 price target on the stock in a report on Wednesday, July 18th. Three investment analysts have rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the stock. The company presently has an average rating of Hold and a consensus price target of $20.50.
NASDAQ EPZM traded down $0.04 during trading on Wednesday, reaching $7.75. 582,696 shares of the company’s stock traded hands, compared to its average volume of 659,433. The company has a market capitalization of $627.01 million, a price-to-earnings ratio of -3.56 and a beta of 1.89. Epizyme has a 12-month low of $7.41 and a 12-month high of $21.40.
Epizyme (NASDAQ:EPZM) last posted its earnings results on Friday, November 2nd. The biopharmaceutical company reported ($0.54) EPS for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.07. As a group, equities research analysts expect that Epizyme will post -1.96 earnings per share for the current year.
In other news, Director David M. Mott purchased 416,667 shares of the stock in a transaction dated Friday, October 5th. The shares were acquired at an average cost of $9.00 per share, for a total transaction of $3,750,003.00. Following the acquisition, the director now owns 12,088 shares of the company’s stock, valued at $108,792. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. 21.50% of the stock is currently owned by company insiders.
A number of hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. boosted its stake in Epizyme by 1.4% in the 3rd quarter. BlackRock Inc. now owns 4,362,472 shares of the biopharmaceutical company’s stock worth $46,242,000 after purchasing an additional 58,752 shares in the last quarter. AXA acquired a new stake in Epizyme in the 3rd quarter worth approximately $714,000. Jennison Associates LLC boosted its stake in Epizyme by 0.7% in the 3rd quarter. Jennison Associates LLC now owns 2,201,037 shares of the biopharmaceutical company’s stock worth $23,331,000 after purchasing an additional 16,249 shares in the last quarter. Alps Advisors Inc. boosted its stake in Epizyme by 22.0% in the 3rd quarter. Alps Advisors Inc. now owns 122,992 shares of the biopharmaceutical company’s stock worth $1,304,000 after purchasing an additional 22,150 shares in the last quarter. Finally, Northern Trust Corp boosted its stake in Epizyme by 12.1% in the 2nd quarter. Northern Trust Corp now owns 651,179 shares of the biopharmaceutical company’s stock worth $8,823,000 after purchasing an additional 70,281 shares in the last quarter. Institutional investors own 74.09% of the company’s stock.
Epizyme Company Profile
Epizyme, Inc, a clinical stage biopharmaceutical company, discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial in elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function,; and Phase Ib/II clinical trial for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer, as well as Phase II clinical trial in adult patients with ovarian cancer.
See Also: Can individual investors take part in an IPO?
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.